What is the recommended management for benign prostatic hyperplasia (BPH)?

Management of Benign Prostatic Hyperplasia (BPH)

For men with mild symptoms (AUA score <7) or non-bothersome symptoms regardless of severity, watchful waiting is the standard approach, as the risks of medical therapy outweigh benefits when symptoms don't impact quality of life. 1

Initial Symptom Assessment and Stratification

• Use the AUA Symptom Index (range 0-35) to quantify severity: mild (1-7), moderate (8-19), severe (20-35) 1
• Assess whether symptoms are "bothersome" (interfering with daily activities), as this determines treatment candidacy more than severity alone 1
• Perform digital rectal examination to assess prostate size and rule out malignancy 2
• Obtain serum PSA and urinalysis to exclude infection, genitourinary cancer, or calculi 2
• Evaluate for serious BPH complications requiring surgical intervention: refractory urinary retention, recurrent UTIs, bladder stones, renal insufficiency, or gross hematuria 1

Treatment Algorithm by Symptom Severity

Mild or Non-Bothersome Symptoms (AUA Score <7 or any score without bother)

• Standard: Watchful waiting only 1
• No medical therapy indicated, as risks exceed benefits in this population 1
• Men with moderate-to-severe symptom frequency but no bother should not receive active treatment 1

Bothersome Moderate-to-Severe Symptoms (AUA Score ≥8 with bother)

Medical therapy options should be selected based on prostate size and treatment goals:

For Symptom Relief Without Enlarged Prostate:

• First-line: Alpha-blockers (alfuzosin, doxazosin, tamsulosin, terazosin, silodosin) provide 4-6 point improvement in AUA Symptom Index 1
• Alpha-blockers are most effective for symptom relief regardless of prostate size 1
• Tamsulosin has lower orthostatic hypotension risk but higher ejaculatory dysfunction rates compared to other alpha-blockers 1
• Caution: In men with hypertension and cardiac risk factors, doxazosin monotherapy increases congestive heart failure risk; manage hypertension separately 1

For Enlarged Prostate (>30cc or PSA >1.5 ng/mL):

• 5-alpha reductase inhibitors (5-ARIs) (finasteride or dutasteride) reduce prostate volume 15-25% at 6 months 1
• 5-ARIs provide 3-point AUA Symptom Index improvement but are less effective than alpha-blockers for symptom relief 1
• Critical indication: 5-ARIs reduce risk of acute urinary retention and need for BPH-related surgery, with benefit increasing with larger prostate volume and higher PSA 1
• Do not use 5-ARIs in men without prostatic enlargement 1
• Counsel patients on slow onset of action (6-12 months for full effect) and sexual side effects (decreased libido, ejaculatory dysfunction, erectile dysfunction) 1
• PSA monitoring: After 1 year of 5-ARI therapy, double the measured PSA value to accurately screen for prostate cancer 1

For Large Prostate (>30cc) with High Progression Risk:

• Combination therapy (alpha-blocker + 5-ARI) is most effective for preventing disease progression 1
• Long-term benefits (5-year data): 67% reduction in overall progression risk, 79% reduction in acute urinary retention, 67% reduction in need for surgery 1
• Best-tested combination: doxazosin + finasteride 1
• Target patients: Those with larger glands, higher PSA values, and desire to avoid future surgery 1
• Short-term studies (≤1 year) show no advantage over alpha-blocker monotherapy, but long-term data demonstrate clear superiority 1

Adjunctive Options:

• Phosphodiesterase-5 inhibitors (tadalafil, sildenafil, vardenafil) provide modest symptom improvement and may be considered, particularly in men with concurrent erectile dysfunction 1, 3
• Beta-3 agonists may provide additional relief for storage symptoms in select patients 3

Surgical and Minimally Invasive Options

Indications for surgical referral: 1, 4

• BPH-related complications (refractory retention, recurrent UTIs, bladder stones, renal insufficiency, gross hematuria)
• Medical therapy failure
• Patient preference

Surgical options include: 1, 5

• TURP (transurethral resection of prostate) - gold standard
• Laser enucleation (HoLEP)
• Photoselective vaporization (PVP)
• Water vapor thermal therapy (WVTT)
• Prostate artery embolization (PAE) - particularly for large prostates, significant comorbidities, or ongoing anticoagulation 6, 5

Preoperative 5-ARI consideration: May reduce intraoperative bleeding and transfusion need after TURP or other surgical intervention 1

Common Pitfalls to Avoid

• Do not prescribe 5-ARIs for symptom relief alone - they are less effective than alpha-blockers and only indicated when prostatic enlargement is documented 1
• Do not treat non-bothersome symptoms - risks outweigh benefits regardless of AUA score 1
• Do not assume alpha-blockers manage hypertension adequately in men with cardiac risk factors - separate antihypertensive management is required 1
• Do not use herbal supplements (saw palmetto, pygeum) - no evidence supports efficacy 4, 2
• Do not forget to adjust PSA interpretation in men on 5-ARIs - double the measured value after 1 year of therapy 1